Hi Marz Am writing this pre espresso ...so reserve the right to correct myself once I'm caffeinated :-)
We know the composite rate is 4.84 % and this composite is tracking as expected . We don't know the numbers used to create this composite .
The Placebo arm could be 5.8% or higher OR as the company has allowed ...as low as 5.2%. We obviously don't know the active arm % but you can see that there are multiple combinations that will yield close to a 4.84% composite.
A 5.2% placebo and a 4.4% active arm = 4.8% composite A 5.8% placebo and a 3.8% active arm =4.8% composite
Both of these scenario's ( and multiple in between ) fit within the companies guidance .
Just my pre espresso pt of view Kiwi
PS IMHO LDL levels are just one of many factors to consider . As Dr Ballantyne ( Anchor trial ) has pointed out ...event rates drop the most when BOTH LDL and HsCrp levels are reduced. Since LDL and HsCRP will be lower in both arms of R-IT ...vs JELIS ...because of the use of high intensity Statins , it remains to be seen the extent of benefit derived from the 4 gms of Vascepa added for the active arm . I believe there will be benefit from the synergy with the Statins ( as Zumantu posted ) and by raising the EPA serum blood level ...just don't know how much
Market Data 
Markets 
AI
